Verona Pharma plc, a clinical stage biopharmaceutical company that discovers and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The company’s lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma.

Foresite Capital was one of the lead investors in Verona’s initial public offering in April 2017. We believe Verona’s most advanced product candidate, RPL554, has a significant advantage in treating obstructive pulmonary disease by working both as an anti-inflammatory and bronchodilator (two clinical effects that have not been achieved with other drugs). Verona has also demonstrated early clinical data showing tolerability and synergy with existing COPD bronchodilators which would enable them to either commercialize as a monotherapy or add-on agent to COPD standard of care.